Tretinoin Monograph: Indications and Safety
Tretinoin is a topical retinoid (a vitamin A derivative applied directly to the skin) authorised by the MHRA. In the UK, it is licensed to treat acne vulgaris (a long-term skin condition causing spots and inflamed lesions). Tretinoin accelerates epidermal cell turnover (the rate at which skin sheds and renews itself). This process reduces comedone formation (clogged hair follicles known as blackheads or whiteheads) and promotes clearer skin.
Core Chemical and Pharmacological Profile
| Parameter | Clinical Specification |
|---|---|
| Active Substance / Salt | Tretinoin (All-trans retinoic acid) |
| IUPAC / Chemical Class | Retinoid / Vitamin A Derivative |
| Pharmacological Category | Topical Retinoid |
| ATC Code | D10AD01 |
| Bioavailability | Minimal percutaneous absorption (< 5% systemic absorption) |
| Plasma Protein Binding | Exceeds 95% (primarily to serum albumin) |
| Elimination Half-Life (t½) | 0.5 to 2 hours (systemic clearance) |
| Primary Clearance Route | Hepatic metabolism via CYP450 isoenzymes |
| UK Regulatory Status | POM (Prescription-Only Medicine) |
Mechanism of Action and Pharmacodynamics
Tretinoin binds directly to nuclear retinoic acid receptors inside epidermal skin cells. This binding alters gene transcription to stimulate skin cell division. Accelerated cell turnover helps shed older surface skin cells rapidly.
This action exerts a comedolytic (pore-unclogging) effect on hair follicles. Tretinoin decreases the cohesiveness (stickiness) of follicular epithelial cells. It prevents microcomedones (microscopic early clogged pores) from developing into active spots.
Tretinoin also reduces cutaneous inflammation (skin redness and swelling). It inhibits inflammatory mediator pathways within the skin layers. This restores normal follicular desquamation (natural shedding of outer skin cells).
Pharmacokinetics (PK) Summary
- Absorption: Tretinoin exhibits low percutaneous (skin surface) absorption following topical application. Systemic bioavailability remains below 5% in normal skin. Cmax occurs between 1 and 4 hours post-application.
Distribution: Systemically absorbed tretinoin binds heavily to plasma proteins. Protein binding exceeds 95%, primarily to serum albumin. The volume of distribution remains low because only a small fraction enters systemic circulation.
- Metabolism: Hepatic (liver) enzymes metabolise the small fraction of absorbed tretinoin. The process involves CYP450 isoenzymes, primarily CYP2C8 and CYP3A4. Metabolism forms inactive retinoic acid metabolites.
- Excretion: Inactive metabolites are excreted through renal (kidney) and biliary (liver bile) routes. The elimination half-life (t½) ranges from 0.5 to 2 hours. Systemic accumulation does not occur with standard topical use.
Approved MHRA Clinical Indications
The MHRA authorises tretinoin in the UK for topical management of acne vulgaris. It treats mild to moderate inflammatory and non-inflammatory acne presentations. Prescribers select tretinoin cream or gel formulations depending on skin sensitivity.
Prescribers select from various licensed tretinoin strengths, typically starting beginners on tretinoin 0.025 cream (often formulated as a tretinoin 0.025 topical cream). Depending on patient response and tolerance, clinicians may gradually adjust treatment to tretinoin 0.05 cream or tretinoin 0.1 cream. UK clinical guidelines recommend starting with lower-strength formulations applied once daily at night to dry skin.
Dosage adjustments are generally unnecessary for hepatic or renal impairment. Minimal systemic absorption limits the risk of organ toxicity. However, careful monitoring ensures optimal cutaneous (skin) safety during treatment.
Contraindications and Drug Interactions
Absolute Contraindications:
Tretinoin is strictly contraindicated during pregnancy due to teratogenic (ability to cause severe birth defects) risks. Women planning pregnancy or breastfeeding must avoid tretinoin use. Patients with a known hypersensitivity (severe allergic reaction) to retinoids must not use it. Furthermore, use caution around thin periorbital tissue; when evaluating tretinoin under the eyes before and after, note that eyelid skin is particularly prone to severe irritation and desquamation.
Drug-Drug Interactions:
- Major: Concomitant use with photosensitising agents (medicines increasing sunlight sensitivity) increases sunburn risk.
- Moderate: Topical keratolytics (skin-peeling agents like benzoyl peroxide) increase skin irritation when used simultaneously.
- Minor: Abrasive soaps or severe astringents (skin-tightening cleansers) increase skin dryness.
Non-Promotional Compliance Information
In the UK, Tretinoin (tretinoin) is regulated under MHRA guidelines. Prescription-Only Medicines (POM) require a valid NHS or private prescription issued by a qualified UK prescriber. Patients cannot obtain tretinoin without a valid prescription from a healthcare professional. While private dispensing fees for topical retinoid formulations vary across registered providers, sourcing medicines through verified regulated channels ensures complete safety and authenticity. Accessing treatment responsibly ensures that patients receive authentic, MHRA-compliant medicines.
Accessing Treatment Safely in the UK
In the UK, the MHRA regulates tretinoin. To buy tretinoin cream legally, patients need a valid NHS or private prescription from a qualified UK prescriber. Pharmacy (P) medicines may be dispensed over the counter after a healthcare screening questionnaire, under the supervision of a registered pharmacist.
Adverse Effects Profile
Side effects are categorised using standard CIOMS frequency thresholds:
- Common (≥ 1/100 to < 1/10): Erythema (skin redness), desquamation (skin peeling), skin dryness, burning sensation, and pruritus (severe skin itching).
- Uncommon (≥ 1/1,000 to < 1/100): Hyperpigmentation (temporary skin darkening), hypopigmentation (skin lightening), and severe photosensitivity (heightened sunlight sensitivity).
- Rare / Serious (< 1/1,000): Severe contact dermatitis (inflammatory skin reaction from allergen exposure) and intense blistering.
Adverse Reaction Reporting: Healthcare professionals and patients should report suspected adverse drug reactions (ADRs) directly to the MHRA via the Yellow Card Scheme at yellowcard.mhra.gov.uk or via the MHRA Yellow Card app.
Frequently Asked Questions
Q: How quickly does tretinoin start working?
A: Tretinoin increases epidermal turnover (skin cell renewal rate) within two to three weeks of initial application. To see a visible reduction in comedones (clogged pores forming blackheads or whiteheads), it usually takes eight to twelve weeks of consistent use. Patients often experience transient erythema (temporary skin redness) during the initial weeks of treatment.
Q: What is the maximum recommended daily frequency for tretinoin?
A: You must apply tretinoin topically (applied directly to the skin) once daily at night. Applying tretinoin more frequently increases the risk of cutaneous irritation (severe skin peeling and burning). Always apply a thin layer to clean, completely dry skin to minimise adverse reactions.
Q: Can you consume alcohol while taking tretinoin?
A: Moderate alcohol intake does not directly impair topical (skin-applied) tretinoin therapy. However, excessive alcohol consumption can aggravate systemic dehydration (body fluid loss) and worsen facial flushing. Avoid harsh alcohol-based toners (skin cleansers containing alcohol) because they intensify skin dryness and irritation.
Q: What is the legal access framework for tretinoin in the UK?
A: Classified strictly as a Prescription-Only Medicine (POM), tretinoin requires formal clinical evaluation by an authorised UK prescriber prior to pharmacy dispensing.
Clinical References and Citations
- MHRA Summary of Product Characteristics (SmPC via eMC): Tretinoin Cream and Gel (medicines.org.uk)
- National Institute for Health and Care Excellence (NICE) Guidelines: Acne Vulgaris Management (nice.org.uk)
Medical Disclaimer
This guide is an educational reference monograph provided for informational purposes only. It does not replace independent clinical judgement or direct consultation with a qualified UK healthcare professional. Prescription-Only Medicines (POMs) are supplied only after a successful medical consultation.